MARKET

GMAB

GMAB

Genmab
NASDAQ

Real-time Quotes | Nasdaq Last Sale

36.03
+0.70
+1.98%
After Hours: 36.03 0 0.00% 16:00 07/15 EDT
OPEN
35.73
PREV CLOSE
35.33
HIGH
36.17
LOW
35.53
VOLUME
532.36K
TURNOVER
--
52 WEEK HIGH
36.17
52 WEEK LOW
16.24
MARKET CAP
23.40B
P/E (TTM)
67.93
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average GMAB stock price target is 36.10 with a high estimate of 40.00 and a low estimate of 30.00.

EPS

GMAB News

More
The Daily Biotech Pulse: Blueprint, Roche Ink $1.7B Cancer Drug Collaboration, INmune's Positive Alzheimer's Readout, Edwards, Abbott Settle Patent Lawsuits
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 13)
Benzinga · 1d ago
Genmab's Shares March Higher, Can It Continue?
Zacks · 5d ago
The Daily Biotech Pulse: Ziopharm Starts Blood Cancer Study, Allergan's Botox Gets Label Expansion, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 9) Affimed NV (NASDAQ: AFMD)
Benzinga · 5d ago
The Daily Biotech Pulse: FDA Nod For Osmotica, OptiNose Strikes Co-promotion Deal, Orphan Drug Designation For AnaptysBio
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8)
Benzinga · 6d ago
The Daily Biotech Pulse: Intersect ENT Jumps On M&A Speculation, VIVUS Files For Bankruptcy
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7)
Benzinga · 07/08 11:31
3 Best-Performing Dividend Aristocrats in the First Half of 2020: Are They Buys Now?
MotleyFool.com · 07/07 10:41
FDA lifts partial hold on mid-stage study of ADC Therapeutics' camidanlumab tesirine
The FDA has removed its partial clinical hold on a pivotal Phase 2 clinical trial evaluating ADC Therapeutics' (NYSE:ADCT) antibody-drug conjugate camidanl
seekingalpha · 07/06 17:10
5 Booming Biotech Stocks to Buy
Kiplinger · 07/03 17:36

Industry

Biotechnology & Medical Research
+1.38%
Pharmaceuticals & Medical Research
+1.63%

Hot Stocks

Symbol
Price
%Change

About GMAB

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer, with a focus on solid tumors and hematological cancer. The Company has two approved antibodies: DARZALEX (daratumumab) and Arzerra (ofatumumab). DARZALEX is approved in combination with other standard therapies in frontline multiple myeloma, relapsed/refractory multiple myeloma and as a monotherapy for heavily pretreated or double-refractory multiple myeloma. It is marketed in the United States (U.S.), Europe and Japan. Arzerra is approved in certain territories for various chronic lymphocytic leukemia (CLL) indications and is marketed in the U.S. and Japan. The Company also develops a broad clinical and pre-clinical product pipeline, both own and partnered, and owns four proprietary antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
More

Webull offers kinds of Genmab A/S stock information, including NASDAQ:GMAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GMAB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GMAB stock methods without spending real money on the virtual paper trading platform.